Are Analysts Bullish United Therapeutics Corporation (NASDAQ:UTHR) After Last Week?

Out of 11 analysts covering United Therapeutics (NASDAQ:UTHR), 7 rate it “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. United Therapeutics was the topic in 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Barclays Capital maintained the stock on February 26 with “Equal-Weight” rating. Below is a list of United Therapeutics Corporation (NASDAQ:UTHR) latest ratings and price target changes.

26/02/2016 Broker: Barclays Capital Rating: Equal-Weight Old Target: $155.00 New Target: $145.00 Maintain

The stock increased 1.51% or $1.86 during the last trading session, hitting $124.64. United Therapeutics Corporation (NASDAQ:UTHR) has declined 24.34% since August 14, 2015 and is downtrending. It has underperformed by 22.43% the S&P500.

United Therapeutics Corporation is a biotechnology company. The company has a market cap of $5.88 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has 9.66 P/E ratio. The Company’s key therapeutic products and product candidates include Remodulin, Tyvaso , Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others.

The institutional sentiment decreased to 0.88 in Q3 2015. Its down 0.19, from 1.07 in 2015Q2. The ratio turned negative, as 52 funds sold all United Therapeutics Corporation shares owned while 131 reduced positions. 36 funds bought stakes while 125 increased positions. They now own 46.84 million shares or 7.07% less from 50.41 million shares in 2015Q2.

Palo Alto Investors Llc holds 9.62% of its portfolio in United Therapeutics Corporation for 1.52 million shares. Krensavage Asset Management Llc owns 199,573 shares or 9.48% of their US portfolio. Moreover, Amici Capital Llc has 4.73% invested in the company for 752,919 shares. The New York-based Sio Capital Management Llc has invested 3.39% in the stock. Maryland Capital Management, a Maryland-based fund reported 146,580 shares.

Since February 25, 2015, the stock had 0 buys, and 15 selling transactions for $10.15 million net activity. Rothblatt Martine A sold 9,662 shares worth $1.18M. Mahon Paul A sold 6,000 shares worth $776,280. Dwek Raymond sold 3,000 shares worth $393,958. Thompson Tommy G sold 5,000 shares worth $695,935. The insider Causey Christopher sold 1,500 shares worth $250,181.

United Therapeutics Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.

Add Comment